Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Revenue of Verona Pharma plc (VRNA)
Revenue in 2023 (TTM): $
According to Verona Pharma plc's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Verona Pharma plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-679,624 | $-52,467,585 | $-55,212,180 | $-54,369,000 |
| 2022 | $458 K | $112 K | $-67,291,000 | $-68,448,000 | $-68,701,000 |
| 2021 | $40 M | $40 M | $-42,189,721 | $-55,587,000 | $-55,569,000 |
| 2020 | $ | $-627,846 | $-47,814,243 | $-65,000,000 | $-65,146,000 |
| 2019 | $2.35 K | $-509,760 | $-32,165,862 | $-51,405,570 | $-41,879,950 |
| 2018 | $2.78 K | $2.78 K | $-25,498,000 | $-30,622,526 | $-25,252,512 |
| 2017 | $1.84 M | $1.84 M | $-29,638,000 | $-34,059,489 | $-27,699,772 |
| 2016 | $ | $ | $-6,959,000 | $-7,369,003 | $-6,191,725 |
| 2015 | $ | $ | $-8,923,000 | $-13,224,220 | $-10,987,967 |
| 2014 | $ | $ | $-3,741,825 | $-5,856,673 | $-4,293,877 |
| 2013 | $ | $ | $-2,784,230 | $-4,640,522 | $-4,163,303 |
| 2012 | $ | $ | $-2,558,329 | $-4,145,331 | $-4,067,651 |
| 2011 | $ | $ | $-2,862,998 | $-2,862,998 | $-2,670,476 |
| 2010 | $ | $ | $-2,881,529 | $-2,913,940 | $-2,921,657 |
| 2009 | $ | $ | $-2,585,580 | $-2,585,580 | $-2,585,580 |
| 2008 | $ | $ | $-1,938,876 | $-1,966,699 | $-2,007,703 |
| 2007 | $ | $ | $-2,385,721 | $-2,413,485 | $-2,413,485 |
| 2006 | $ | $ | $-1,187,281 | $-1,191,199 | $-1,191,199 |
| 2005 | $ | $ | $-12,045 | $44.74 K | $44.74 K |